Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0542-0
Abstract: SummaryBackground To evaluate the efficacy and safety of doxorubicin (ADM) combined with thalidomide (THA) as a first-line treatment for patients with refractory aggressive fibromatosis (AF). Patients and Methods Eligible patients were treated with ADM 30 mg/m2… read more here.
Keywords: study doxorubicin; refractory aggressive; patients refractory; phase study ... See more keywords